Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Ontology highlight
ABSTRACT: Cancer immunotherapy was selected as the Breakthrough of the Year 2013 by the editors of Science, in part because of the successful treatment of refractory hematological malignancies with adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells. Effective treatment of B cell leukemia may pave the road to future treatment of solid tumors, using similar approaches. The prostate expresses many unique proteins and, since the prostate gland is a dispensable organ, CAR T cells can potentially be used to target these tissue-specific antigens. However, the location and composition of prostate cancer metastases complicate the task of treating these tumors. It is therefore likely that more sophisticated CAR T cell approaches are going to be required for prostate metastasis than for B
SUBMITTER: Hillerdal V
PROVIDER: S-EPMC4544486 | biostudies-literature | 2015 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA